Literature DB >> 16281459

Sensitivity analysis of causal inference in a clinical trial subject to crossover.

Hui Xie1, Daniel F Heitjan.   

Abstract

In many clinical trials it is possible for some subjects to cross over between treatment arms. One can evaluate the effect of crossover by modeling it as a missing-data problem, where for subjects who cross over, one treats the unobserved value of the outcome in the original randomization arm as the missing data. The as-treated analysis is invalid if the crossover is nonignorable, in the sense that the crossovers represent a nonrandom sample of the randomized subjects. A recent area of general interest is the development of methods for measuring the sensitivity of inferences to nonignorability in the missing-data mechanism; one such approach is that of Troxel et al. In this paper we apply their method to the problem of measuring sensitivity to nonignorable crossover in randomized trials, extending it to the case where the crossover mechanism may differ between arms. Our method allows us to identify circumstances under which the as-treated analysis may be more or less sensitive to nonignorable crossover. We illustrate it with the example of a randomized clinical trial (RCT) in multiple sclerosis and a study of the effect of military service on income.

Entities:  

Mesh:

Year:  2004        PMID: 16281459     DOI: 10.1191/1740774504cn005oa

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  7 in total

1.  A tractable method to account for high-dimensional nonignorable missing data in intensive longitudinal data.

Authors:  Chengbo Yuan; Donald Hedeker; Robin Mermelstein; Hui Xie
Journal:  Stat Med       Date:  2020-05-05       Impact factor: 2.373

2.  Sensitivity of the discrete-time Kaplan-Meier estimate to nonignorable censoring: Application in a clinical trial.

Authors:  Tao Liu; Daniel F Heitjan
Journal:  Stat Med       Date:  2012-07-16       Impact factor: 2.373

Review 3.  Controversial role of arthroscopic meniscectomy of the knee: A review.

Authors:  Austin Y Ha; Robert M Shalvoy; Anne Voisinet; Jennifer Racine; Roy K Aaron
Journal:  World J Orthop       Date:  2016-05-18

4.  A scalable approach to measuring the impact of nonignorable nonresponse with an EMA application.

Authors:  Weihua Gao; Donald Hedeker; Robin Mermelstein; Hui Xie
Journal:  Stat Med       Date:  2016-08-18       Impact factor: 2.373

Review 5.  OARSI Clinical Trials Recommendations: Design and conduct of clinical trials of surgical interventions for osteoarthritis.

Authors:  J N Katz; E Losina; L S Lohmander
Journal:  Osteoarthritis Cartilage       Date:  2015-05       Impact factor: 6.576

6.  Assessing complier average causal effects from longitudinal trials with multiple endpoints and treatment noncompliance: An application to a study of Arthritis Health Journal.

Authors:  Lulu Guo; Yi Qian; Hui Xie
Journal:  Stat Med       Date:  2022-03-10       Impact factor: 2.497

Review 7.  The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial.

Authors:  Mike Hernandez; J Jack Lee; Beow Y Yeap; Rong Ye; Robert L Foote; Paul Busse; Samir H Patel; Roi Dagan; James Snider; Nasiruddin Mohammed; Alexander Lin; Pierre Blanchard; Scott B Cantor; Menna Y Teferra; Kate Hutcheson; Pablo Yepes; Radhe Mohan; Zhongxing Liao; Thomas F DeLaney; Steven J Frank
Journal:  Adv Radiat Oncol       Date:  2020-12-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.